SG Americas Securities LLC Raises Holdings in Juno Therapeutics, Inc. (JUNO)

SG Americas Securities LLC raised its position in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 9.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,254 shares of the biopharmaceutical company’s stock after buying an additional 1,328 shares during the quarter. SG Americas Securities LLC’s holdings in Juno Therapeutics were worth $684,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JUNO. Teachers Advisors LLC lifted its stake in Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock valued at $1,428,000 after buying an additional 3,531 shares during the last quarter. Aperio Group LLC lifted its stake in Juno Therapeutics by 11.9% in the second quarter. Aperio Group LLC now owns 28,360 shares of the biopharmaceutical company’s stock valued at $848,000 after buying an additional 3,024 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Juno Therapeutics by 64.6% in the second quarter. Russell Investments Group Ltd. now owns 17,684 shares of the biopharmaceutical company’s stock valued at $528,000 after buying an additional 6,943 shares during the last quarter. Pictet Asset Management Ltd. lifted its stake in Juno Therapeutics by 20.5% in the second quarter. Pictet Asset Management Ltd. now owns 463,435 shares of the biopharmaceutical company’s stock valued at $10,766,000 after buying an additional 78,690 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in Juno Therapeutics by 70.1% in the second quarter. Canada Pension Plan Investment Board now owns 160,600 shares of the biopharmaceutical company’s stock valued at $4,800,000 after buying an additional 66,200 shares during the last quarter. Institutional investors own 70.37% of the company’s stock.

In related news, EVP Robert Azelby sold 12,850 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total transaction of $577,607.50. Following the transaction, the executive vice president now owns 37,439 shares of the company’s stock, valued at $1,682,883.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. Insiders have sold 54,801 shares of company stock worth $2,527,741 in the last ninety days. 15.08% of the stock is currently owned by corporate insiders.

JUNO has been the subject of several analyst reports. Maxim Group restated a “buy” rating and set a $56.00 price target (up previously from $34.00) on shares of Juno Therapeutics in a research note on Monday, October 9th. Cowen restated a “buy” rating and set a $49.00 price target on shares of Juno Therapeutics in a research note on Friday, October 27th. Citigroup restated a “buy” rating and set a $59.00 price target on shares of Juno Therapeutics in a research note on Tuesday, October 31st. SunTrust Banks upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 2nd. Finally, Morgan Stanley restated an “equal weight” rating and set a $43.00 price target (up previously from $27.00) on shares of Juno Therapeutics in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $45.48.

Juno Therapeutics, Inc. (JUNO) opened at $56.73 on Friday. Juno Therapeutics, Inc. has a twelve month low of $17.52 and a twelve month high of $63.45. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the company posted ($0.57) earnings per share. Juno Therapeutics’s quarterly revenue was up 115.4% on a year-over-year basis. research analysts anticipate that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current year.

WARNING: “SG Americas Securities LLC Raises Holdings in Juno Therapeutics, Inc. (JUNO)” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/12/08/sg-americas-securities-llc-raises-holdings-in-juno-therapeutics-inc-juno.html.

Juno Therapeutics Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply